Effect of a Novel Antidepressant and Anticancer Nuc01 on Depression in Cancer Survivors.

Changchun Yuan, Xudong Shi, Zhiqiang Wang, Yuqiang Li, Wenbing Ma, Kai Fu

Abstract read

In one paragraph

Article in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Changchun YuanSchool of Chemistry and Chemical Engineering, North University of China, Taiyuan 030051, China.ORCID 0000-0002-2889-4566

Xudong ShiSchool of Chemistry and Chemical Engineering, North University of China, Taiyuan 030051, China.

Zhiqiang WangSchool of Chemistry and Chemical Engineering, North University of China, Taiyuan 030051, China.

Yuqiang LiSchool of Chemistry and Chemical Engineering, North University of China, Taiyuan 030051, China.

Wenbing MaSchool of Chemistry and Chemical Engineering, North University of China, Taiyuan 030051, China.

Kai FuSchool of Chemistry and Chemical Engineering, North University of China, Taiyuan 030051, China.

Funding

Fundamental Research Program of Shanxi Province 202203021222040National Natural Science Foundation of China 22371266Natural Science Foundation of Shandong Province ZR2023MB043

6 · The paper itself

Abstract

Depression in cancer survivors is commonly treated with serotonin and norepinephrine reuptake inhibitors (SNRIs), such as venlafaxine. These drugs alleviate depressive symptoms by inhibiting the reuptake of serotonin and norepinephrine. However, a novel approach has emerged with the development of

Indexed as

anticancerantidepressantLSD1 inhibitorPCPA–desvenlafaxine conjugate

Identifiers

PMID40864741

DOI10.3390/cimb47080587

PMCPMC12384447

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.